SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Price, Quote, News and Overview
NASDAQ:SHPH - Nasdaq - US8256933024 - Common Stock - Currency: USD
SHPH Quote, Performance and Key Statistics
SHUTTLE PHARMACEUTICALS HOLD
NASDAQ:SHPH (2/5/2025, 8:26:59 PM)
After market: 0.67 0 (-0.01%)0.6701
-0.04 (-5.62%)
The current stock price of SHPH is 0.6701 USD. In the past month the price decreased by -24.71%. In the past year, price decreased by -77.36%.
SHPH Latest News, Press Releases and Analysis
These stocks are moving in today's after hours session
Wednesday's after hours session: top gainers and losers
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a...
SHPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About SHPH
Company Profile
Shuttle Pharmaceuticals Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland and currently employs 8 full-time employees. The company went IPO on 2022-08-31. Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The firm is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). The company is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
Company Info
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 8
Company Website: https://shuttlepharma.com/
Investor Relations: http://www.shuttlepharma.com/investor-relations
Phone: 12404034212
SHPH FAQ
What is the stock price of SHPH?
The current stock price of SHPH is 0.6701 USD.
What is the symbol for SHUTTLE PHARMACEUTICALS HOLD stock?
The exchange symbol of SHUTTLE PHARMACEUTICALS HOLD is SHPH and it is listed on the Nasdaq exchange.
On which exchange is SHPH stock listed?
SHPH stock is listed on the Nasdaq exchange.
Is SHPH a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SHPH, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SHPH.
Does SHPH stock pay dividends?
SHPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of SHPH?
SHPH does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
What is the Short Interest ratio of SHPH stock?
The outstanding short interest for SHPH is 0.33% of its float.
SHPH Technical Analysis
SHPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SHPH. Both the profitability and financial health of SHPH have multiple concerns.
SHPH Financial Highlights
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS decreased by -89.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.78% | ||
| ROE | -162.56% | ||
| Debt/Equity | 0.03 |